Clinical Trial: A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07920809) titled 'A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis' on Oct. 16.

Brief Summary: This is a randomized, double-blind, placebo-controlled, Phase Ib study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HSK60002 tablets in approximately 60 participants with moderate-to-severe atopic dermatitis (AD). Participants are randomized within one of three dose groups (10 mg once daily [QD], 30 mg QD, or 30 mg once weekly [QW]) in a 4:1 ratio to HSK60002 or matching placebo. Treatment is given orally for up to 16 weeks (Stage 1: Weeks 1-4; Stage 2: We...